SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Pfizer planning to merge off-patent drug business with Mylan

30 Jul 2019 Evaluate

Pfizer is planning to merger its off-patent drug business with generic drugmaker Mylan to create a global leader in low-cost treatment. The new entity, which will be renamed upon the deal's closure, will have a portfolio that includes impotence drug Viagra, cholesterol pills Lipitor, painkiller Lyrica, and the life-saving EpiPen allergy treatment.

Pfizer has produced innovative breakthroughs in a wide range of research areas, including depression, erectile dysfunction, high cholesterol, HIV infection, hypertension, bacterial infections and systemic fungal infections.

Pfizer Share Price

4850.45 39.40 (0.82%)
11-May-2026 11:22 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1883.75
Dr. Reddys Lab 1290.80
Cipla 1340.10
Zydus Lifesciences 943.70
Lupin 2250.05
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×